On Monday, Xilio Therapeutics Inc (NASDAQ: XLO) opened lower -8.18% from the last session, before settling in for the closing price of $1.10. Price fluctuations for XLO have ranged from $0.50 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 58.99% at the time writing. With a float of $18.77 million, this company’s outstanding shares have now reached $43.96 million.
Let’s determine the extent of company efficiency that accounts for 73 employees. In terms of profitability, gross margin is 82.23%, operating margin of -852.23%, and the pretax margin is -834.92%.
Xilio Therapeutics Inc (XLO) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xilio Therapeutics Inc is 57.29%, while institutional ownership is 16.09%. The most recent insider transaction that took place on Jan 02 ’25, was worth 6,841. In this transaction Chief Financial Officer of this company sold 6,954 shares at a rate of $0.98, taking the stock ownership to the 12,421 shares. Before that another transaction happened on Jan 02 ’25, when Company’s SVP, FINANCE AND ACCOUNTING sold 1,803 for $0.98, making the entire transaction worth $1,774. This insider now owns 3,197 shares in total.
Xilio Therapeutics Inc (XLO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 58.99% per share during the next fiscal year.
Xilio Therapeutics Inc (NASDAQ: XLO) Trading Performance Indicators
Check out the current performance indicators for Xilio Therapeutics Inc (XLO). In the past quarter, the stock posted a quick ratio of 1.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.72, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Xilio Therapeutics Inc (XLO)
Looking closely at Xilio Therapeutics Inc (NASDAQ: XLO), its last 5-days average volume was 0.47 million, which is a drop from its year-to-date volume of 0.53 million. As of the previous 9 days, the stock’s Stochastic %D was 47.04%. Additionally, its Average True Range was 0.13.
During the past 100 days, Xilio Therapeutics Inc’s (XLO) raw stochastic average was set at 36.53%, which indicates a significant decrease from 41.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 178.72% in the past 14 days, which was higher than the 121.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0505, while its 200-day Moving Average is $0.9856. However, in the short run, Xilio Therapeutics Inc’s stock first resistance to watch stands at $1.0900. Second resistance stands at $1.1700. The third major resistance level sits at $1.2400. If the price goes on to break the first support level at $0.9400, it is likely to go to the next support level at $0.8700. Now, if the price goes above the second support level, the third support stands at $0.7900.
Xilio Therapeutics Inc (NASDAQ: XLO) Key Stats
There are currently 43,958K shares outstanding in the company with a market cap of 47.47 million. Presently, the company’s annual sales total 0 K according to its annual income of -76,400 K. Last quarter, the company’s sales amounted to 2,260 K and its income totaled -14,020 K.
